DMAC News - Candlesense

DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restrictio...

How might the sentiment score of 30 influence short‑term technical positioning for DMAC? Are there any regulatory or reimbursement risks mentioned that could impact the company's long‑term prospects? What is the market's reaction to the earnings release and conference call, and are there any notable shifts in trading volume or price momentum?

Earnings

12 days ago

DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia, fetal growth restrictio...

Is there any risk that the new CMO’s integration could lead to delays or operational disruptions that might impact short‑term stock performance? What is the expected reaction of institutional investors and analysts to the leadership change—will it alter consensus estimates or target price? Could the appointment signal a shift in strategic focus or priority within the pipeline that might affect long‑term valuation?

Leadership

18 days ago

DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025

MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for preeclampsia and acute ischemic strok...

What were the notable changes in operating expenses, SG&A, or other cost structures? Are there any changes in the capital raise plans or upcoming financing activities? How might the Q2 results impact the stock’s short‑term technical momentum and trading volumes?

Earnings

19 days ago